Literature DB >> 15497528

Recurrent small-artery disease in hyperhomocysteinemia: widowers' stroke syndrome?

Kazunori Toyoda1, Takeshi Uwatoko, Toshifumi Shimada, Noriko Hagiwara, Shigeru Fujimoto, Setsuro Ibayashi, Yasushi Okada.   

Abstract

Hyperhomocysteinemia is thought to cause ischemic strokes. We report two middle-aged widowers with frequent recurrences of small-artery strokes, two capsular infarcts and a thalamic hemorrhage in one patient, and two thalamic and pontine infarcts in the other. Blood tests following the final stroke showed hyperhomocysteinemia and methylenetetrahydrofolate reductase C677T gene mutation, with low concentration of vitamin B6. Multivitamin supplementation normalized plasma homocysteine levels in both patients. Hyperhomocysteinemia is treatable; therefore, serum homocysteine should be measured as a potential risk factor for stroke recurrence in relatively young patients with recurrent small-artery infarctions or hemorrhage, especially those with insufficient lifestyle factors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15497528     DOI: 10.2169/internalmedicine.43.869

Source DB:  PubMed          Journal:  Intern Med        ISSN: 0918-2918            Impact factor:   1.271


  3 in total

1.  Association of the C677T polymorphism in the MTHFR gene with hemorrhagic stroke: a meta-analysis.

Authors:  Shan Kang; Xinxin Zhao; Lingling Liu; Wenlong Wu; Dongfeng Zhang
Journal:  Genet Test Mol Biomarkers       Date:  2013-02-21

2.  Cerebrovascular risk factors associated with ischemic stroke in a young non-diabetic and non-hypertensive population: a retrospective case-control study.

Authors:  Nan Zhang; Lin Zhang; Qiu Wang; Jingwei Zhao; Jia Liu; Guang Wang
Journal:  BMC Neurol       Date:  2020-11-23       Impact factor: 2.474

3.  Interplay between 3'-UTR polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene and the risk of ischemic stroke.

Authors:  Jung Oh Kim; Han Sung Park; Chang Soo Ryu; Jung-Won Shin; Jinkwon Kim; Seung Hun Oh; Ok Joon Kim; Nam Keun Kim
Journal:  Sci Rep       Date:  2017-09-29       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.